Clinical trials: Infections, Respiratory
Influenza
Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine
To provide Centers for Biologic Evaluation and Research (CBER) with sera collected from healthy children receiving the 2007-2008 formulation of the inactivated, split-virion influenza vaccine Fluzone® for further study.
- Trial name
- NCT00561002
- Testing
- 2007-2008 Influenza Virus Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Coronavirus Disease 2019(COVID-19)
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.
- Trial name
- NCT04483375
- Testing
- SCTA01
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Influenza, Human
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and…
- Trial name
- NCT07204964
- Testing
- Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A)
- Where
- 17 sites in United States, Belgium
- Volunteers
- 971 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Safety of Inhaled Zanamivir in Pregnancy
Zanamivir is a neuraminidase inhibitor that has demonstrated effectiveness against the pandemic H1N1 virus. Zanamivir was first authorized in Sweden in June 1999 and is approved in the European Union (EU) through mutual…
- Trial name
- NCT01462487
- Testing
- Treatment with zanamivir
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
COVID-19 Pneumonia, Virus Diseases
Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease
Dr. Biolyse® is a device with artificial intelligence that works in sync with the immune system and can be integrated like an element of this system. It is designed to develop chemical immunity within the body against infections.
- Conditions
- COVID-19 Pneumonia, Virus Diseases, COVID-19
- Trial name
- DoBiC-19 (NCT06113757)
- Testing
- Signal Therapy provided by Dr.Biolyse device, Liquid Support Treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- AVB Biotechnology
Covid19
Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19
This study is designed rapidly assess safety and preliminary efficacy in hospitalized patients with COVID-19 respiratory distress to provide clinical guidance for possible wider use in treating patients in this pandemic…
- Trial name
- CoronaStem1 (NCT04486001)
- Testing
- PSC-04
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sorrento Therapeutics, Inc.
Influenza, Healthy
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
This study is being conducted to compare the immunogenicity, safety, and viral shedding of a new A/H1N1 strain that will be incorporated into the FluMist quadrivalent formulation for the 2017-2018 influenza season with the…
- Trial name
- FluMist (NCT03143101)
- Testing
- FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018)
- Where
- 12 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Cold, Cold Symptom
Ability of Beta-glucan Supplementation to Augment Immune Function
This proposed study is designed to assess the efficacy of a capsule containing beta-glucan taken orally daily as compared to a placebo capsule on the URTI symptoms, and the immune response change in marathon runners
- Conditions
- Cold, Cold Symptom, Flu, Flu Symptom
- Trial name
- NCT03769012
- Testing
- Beta-Glucan
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kemin Foods LC
Influenza, Human
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)
The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza…
- Trial name
- NCT01390792
- Testing
- Zanamivir hydrate
- Volunteers
- 622 people
- Sponsor
- GlaxoSmithKline
Rhinitis, Seasonal, Allergic
StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study
This active vs active comparative trial will evaluate the safety and efficacy of incremental doses of atropine in combination with pseudoephedrine 120 mg/chlorpheniramine 8 mg in adult patients with a history of seasonal allergic…
- Trial name
- NCT02082054
- Testing
- PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg
- Where
- 4 sites in United States
- Volunteers
- 125 people
- Sponsor
- Magna Pharmaceuticals, Inc.
Influenza
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
The primary objective of the study was to provide sera (collected from participants before vaccination [Blood Sample 1] and after final vaccination [Blood Sample 2]) to the Center for Biologics Evaluation and Research (CBER) for…
- Trial name
- GRC00097 (NCT04109222)
- Testing
- Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, SARS-CoV-2 Infection
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster
This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial. The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral…
- Trial name
- NCT05465902
- Testing
- Recombinant COVID-19 variant Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated, mRNA COVID-19 vaccine (Moderna)
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Covid19
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19
APN01 is a soluble recombinant form of the human angiotensin-converting enzyme 2 (rhACE2) that is currently under development as a therapy for corona-virus-disease 2019 (COVID-19).
- Trial name
- NCT05065645
- Testing
- Angiotensin Converting Enzyme 2, Sodium chloride
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Apeiron Biologics
Prophylaxis of A/H3N2v Influenza
Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
Evaluate the safety and immunogenicity of three dosage levels of swine influenza vaccine in children ages 3 to <9 years, adolescents 9 to <18 years, adults 18 to <65 years and elderly 65 years and older.
- Trial name
- NCT01855945
- Testing
- Swine Influenza
- Where
- 11 sites in United States
- Volunteers
- 627 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
COVID-19
Study of Obeldesivir in Nonhospitalized Participants With COVID-19
The goal of this clinical study is to test if obeldesivir (GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness.
- Trial name
- OAKTREE (NCT05715528)
- Testing
- Obeldesivir
- Where
- 113 sites in United States, Japan
- Volunteers
- 2,011 people
- Sponsor
- Gilead Sciences
Artificial Intelligence, Lung Diseases
Retrospective Study of Carebot AI CXR Performance in Preclinical Practice
The purpose of this study is to describe the design, methodology and evaluation of the preclinical test of Carebot AI CXR software, and to provide evidence that the investigated medical device meets user requirements in…
- Conditions
- Artificial Intelligence, Lung Diseases, Pneumothorax, Pleural Effusion
- Trial name
- NCT05594485
- Testing
- Carebot AI CXR
- Where
- Czechia
- Volunteers
- 127 people
- Sponsor
- Carebot s.r.o.
Influenza
A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older
The aim of the study is to assess the safety and immunogenicity of two formulations of the high-dose quadrivalent influenza vaccine compared to the licensed high-dose trivalent influenza vaccine control in healthy elderly…
- Trial name
- NCT02553343
- Testing
- High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine
- Where
- 9 sites in United States
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Long COVID
Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID
This will be a six-week, randomized, parallel, two group, open-label design. Patients will be treated with Paragon Novel Metabolic Regulator (PNMR) + standard of care (SOC) or SOC alone for 6 weeks for the treatment of Long…
- Trial name
- NCT07627815
- Testing
- Paragon Novel Metabolic Regulator (PNMR), Dietary and Lifestyle Recommendations
- Where
- 4 sites in Canada
- Volunteers
- 82 people
- Sponsor
- ParagonClinicals Inc.
Ventilator Associated Pneumonia
PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB
A multicenter Phase 2 study to evaluate the pharmacokinetics, efficacy, and safety of intravenous BV100 combined with Polymyxin B in adult patients with VABP suspected or confirmed to be due to CRAB
- Trial name
- NCT05685615
- Testing
- BV100 plus Polymyxin B, BAT
- Where
- 16 sites in Georgia, Greece and 1 more
- Volunteers
- 39 people
- Sponsor
- BioVersys AG
Bacterial Infections, Urinary Tract Infections
Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers
This Phase I study is a randomized, double-blind, placebo-controlled, dose-escalation trial conducted at a single center. It consists of two parts: Part 1 (SAD): Evaluates the safety, tolerability, and pharmacokinetics (PK) of…
- Conditions
- Bacterial Infections, Urinary Tract Infections, Intra-Abdominal Infections, Respiratory Tract Infections
- Trial name
- NCT07207291
- Testing
- JKN2501
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.